Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 19/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239182 | 1.00 | P2RX4 (0.72) | P2RX4NPC1ALDH1A1TP53MAPT | |
| SCHEMBL30297454 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL30297447 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL16239220 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL16239174 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL16239096 | 0.89 | P2RX4 (0.73) | P2RX4MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30297215 | 0.89 | P2RX4 (0.73) | P2RX4MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL16239170 | 0.89 | P2RX4 (0.72) | P2RX4NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL16239082 | 0.89 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL16238958 | 0.89 | P2RX4 (0.72) | P2RX4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | disclosed |
| US-12090158-B2 | Medicine for diabetic peripheral neuropathy | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-4408432-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023052518-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12090158-B2 | Medicine for diabetic peripheral neuropathy | P2RX4, P2RX3, P2RX1 | P2RX4 1/4885NPC1 770/4885ALDH1A1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.